Medifast (NYSE:MED) Stock Crosses Above 200-Day Moving Average – Here’s What Happened

Medifast Inc (NYSE:MED)’s stock price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $11.15 and traded as high as $12.66. Medifast shares last traded at $12.6250, with a volume of 54,712 shares.

Analyst Upgrades and Downgrades

MED has been the subject of several recent research reports. Weiss Ratings upgraded shares of Medifast from a “sell (e+)” rating to a “sell (d)” rating in a research report on Monday, August 17th. Zacks Research lowered Medifast from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 11th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Reduce” and an average target price of $12.00.

Medifast Price Performance

The stock’s 50-day simple moving average is $11.19 and its two-hundred day simple moving average is $11.15. The firm has a market capitalization of $141.16 million, a P/E ratio of -5.42 and a beta of 0.71.

Medifast (NYSE:MED) last announced its quarterly earnings data on Monday, August 3rd. The specialty retailer reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.37. The firm had revenue of $76.38 million for the quarter, compared to the consensus estimate of $72.70 million. Medifast had a negative net margin of 8.08% and a negative return on equity of 6.69%. Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS. On average, analysts forecast that Medifast Inc will post -1.04 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Parsa Kiai acquired 43,150 shares of the company’s stock in a transaction on Wednesday, August 26th. The stock was acquired at an average price of $12.26 per share, with a total value of $529,019.00. Following the acquisition, the director directly owned 707,492 shares of the company’s stock, valued at approximately $8,673,851.92. This trade represents a 6.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. In the last 90 days, insiders have acquired 119,966 shares of company stock valued at $1,423,576. 3.70% of the stock is owned by insiders.

Hedge Funds Weigh In On Medifast

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MED. Empowered Funds LLC purchased a new stake in shares of Medifast during the 2nd quarter worth approximately $701,000. BlackRock Inc. purchased a new position in shares of Medifast in the second quarter valued at $3,920,000. Great Lakes Advisors LLC bought a new stake in Medifast in the second quarter worth $548,000. Bank of America Corp DE bought a new stake in Medifast in the second quarter worth $924,000. Finally, Chico Wealth RIA bought a new position in Medifast during the second quarter valued at $223,000. 95.51% of the stock is owned by institutional investors.

Medifast Company Profile

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight?loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight?management solutions.